NCAM1 and extranodal nasal NK/T cell lymphoma: To explore a more effective therapeutic strategy for CD56-negative NKTCL, it is important to examine the response and failure rate of chemotherapy with asparaginase-based regimens in a large number of CD56-negative NKTCL cases.